External site

By following this link, you are leaving Medically and entering a website that is not owned or controlled by Roche. Roche does not take any responsibility for access to or use of this website, nor for any content therein.

Leave site
Home ELCC 2023
Roche and Genentech at

ELCC 2023

March 29 - April 01
Copenhagen, Denmark/ Virtual (Hybrid)
esmo.org
Add to calendar
Share feedback
Share page
-
Medical Materials
Agenda
Coming soon
04:06 PM
Duration 12mins Auditorium 1
CONTACT-01: Efficacy and safety from a Ph 3 study of atezolizumab (atezo) + cabozantinib (cabo) vs docetaxel (doc) monotherapy in patients (pts) with metastatic NSCLC (mNSCLC) previously treated with checkpoint inhibitors and chemotherapy
Joel W Neal
Oncology | Lung Cancer

You have successfully signed up for this alert. You will be notified when it is available.

Sign up or login to unlock the full suite of MEDICALLY features
Add to calendar
05:35 PM
Duration 5mins Auditorium 4
Updated survival, efficacy and safety of adjuvant (adj) atezolizumab (atezo) after neoadjuvant (neoadj) atezo in the phase II LCMC3 study
David P. Carbone
Oncology | Lung Cancer

You have successfully signed up for this alert. You will be notified when it is available.

Sign up or login to unlock the full suite of MEDICALLY features
Add to calendar

This website is intended for healthcare professionals outside the United Kingdom (UK) and Australia. Registration status and prescribing information of medicinal products may differ between countries. Please refer to local product information for any medicinal products mentioned on this website.